Tumor immunogenomic features determine outcomes in metastatic colorectal cancer patients treated with standard-of-care combinations of bevacizumab and cetuximab.
暂无分享,去创建一个
M. Bertagnolli | B. Vincent | N. Rashid | H. Lenz | A. Venook | F. Innocenti | F. Ou | C. Blanke | X. Qu | A. Yazdani | Scott Van Buren | O. Kabbarah